Drugs / VNS vaccine
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05084508 | Feb 2022 → Feb 2024 | chickenpox | GlaxoSmithKline | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VNS vaccine | “These results show that the VNS vaccine was immunogenic with an acceptable safety profile following a single dose of all three potencies.” PMID 41825190 ↗ Mar 2026 |
| Known as | VNS | “This study assessed the immunogenicity and safety of the investigational varicella vaccine (VNS) compared to a licensed, current standard-of-care vaccine.” PMID 41825190 ↗ Mar 2026 |
| Modality | Vaccine | “investigational varicella vaccine (VNS)” NCT05084508 ↗ |